Actoferon (IFN beta1b biosimilar) / Actoverco, AMEGA Biotech - LARVOL DELTA

A Randomized, Double-blind Controlled Clinical Study to Determine the Effectiveness, Safety and Tolerability of Actoferon® Compared to Betaferon® in Subjects with Relapsing Remitting Multiple Sclerosis (RRMS) (ECTRIMS 2022) - "There was no significant difference between Betaferon®and Actoferon®in aspects of efficacy, safety and tolerability. This study showed the non-inferiority of Actoferon®to Betaferon®."

Clinical • CNS Disorders • Immunology • Inflammation • Multiple Sclerosis